Simcere Reports Positive Phase IV Interim Results For Lung Cancer Drug Endu
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Simcere Pharmaceutical reported positive interim results for Phase IV clinical trials of its recombinant human endostatin lung cancer drug Endu, the company announced Sept. 3